Skip to main content
Erschienen in: BMC Infectious Diseases 1/2020

Open Access 01.12.2020 | Research article

Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study

verfasst von: Dan Yuan, Meijing Liu, Peng Jia, Yiping Li, Yuling Huang, Li Ye, Laze Api, Maogang Chen, Liang Yao, Zixin Wang, Honglu Liu, Shu Liang, Shujuan Yang

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2020

Abstract

Background

Liangshan Yi Autonomous Prefecture is one of the areas that most severely affected by human immunodeficiency virus (HIV) in China, and virological failure on antiretroviral therapy (ART) is serious in this area. Analyses of prevalence and determinants of ART failure, the genetic diversity and drug resistance among people living with HIV (PLWH) helps improve HIV treatment efficiency and prevent HIV transmission.

Methods

A total of 5157 PLWH were recruited from 2016 to 2017. The venous blood samples were subjected to RT-PCR, followed by sequencing of the HIV-1 pol gene, targeting the protease and reverse transcriptase fragments. HIV-1 diversity was analyzed using the DNAStar software and drug resistance mutations were analyzed using the Stanford University HIV Drug Resistance Database.

Results

A total of 2156 (41.81%) PLWH showed virological failure on ART. Males (ORm = 1.25), heterosexual behaviors and drug injection (ORm = 1.44) and mother to child transmission routes (ORm = 1.58), the clinical stage of AIDS (ORm = 1.35), having used illicit drugs and shared the needles (1–4 times: ORm = 1.34; more than 5 times: ORm = 1.52), having ever replaced ART regimen (ORm = 1.48) increased the risk of virological failure among PLWH, while higher education lever (ORm = 0.77) and ≥ 12 months on ART (12 ~ 36 months: ORm = 0.72; ≥36 months: ORm = 0.66) was associated with lower likelihood of virological failure. The data revealed that CRF07_BC (1508, 95.62%) were the most common strains, and the drug-resistant rate was 32.10% among PLWH with virological failure in this area. The high frequencies of drug resistance were found in EFV and NVP of NNRTIs, ABC, FTC and 3TC of NRTIs, and TPV/r in PIs. The most common mutations in NNRTIs, NRTIs and PIs were K103N/KN (64.69%), M184V/MV/I (36.29%) and Q58E/QE (4.93%), respectively.

Conclusion

We concluded that surveillance of virological failure, HIV-1 subtypes, and drug resistance to understand HIV-1 epidemiology and guide modification of ART guidelines, and target prevention and control strategies should be formatted to reduce the virological failure and drug resistance to promote viral suppression and prevent HIV-1 transmission.
Hinweise
Dan Yuan and Meijing Liu contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
HIV
Human immunodeficiency virus
AIDS
Acquired Immune Deficiency Syndrome
ART
Antiretroviral therapy
PLWH
People living with HIV
VCT
Voluntary Counseling and Testing
NGO
Non-government organization
HSS
HIV sentinel surveillance
RT-PCR
Reverse transcription-polymerase chain reaction
OR
Odds ratios
CI
Confidence interval
NNRTI
Nonnucleoside reverse transcriptase inhibitor
NRTI
Nucleoside reverse transcriptase inhibitor
PI
Protease inhibitor
TDF
Tenofovir
3TC
Lamivudine
NVP
Nevirapine
EFV
Efavirenz
AZT
Zidovudine
LPV/r
Tipranavir/ritonavir
ATV/r
Atazanavir/ritonavir
DRv/r
Darunavir/ritonavir
FPV/r
Tipranavir/ritonavir
IDV/r
Indinavir/Ritonavir
NFV
Nelfinavir
SQV/r
Ritonavir-boosted saquinavir
TPV/r
Tipranavir/ritonavir
ABC
Abacavir
D4T
Stavudine
DDI
Didanosine
FTC
Emtricitabine
ETR
Etravirine
RPV
Rilpivirine

Background

Human immunodeficiency virus (HIV) infections in humans affect more than 37 million individuals worldwide, and approximately 0.85 million people living with HIV (PLWH) live in China. The number of PLWH has increased by 14% from 2016 to 2017 [1]. Liangshan Yi Autonomous Prefecture, as the largest traditional settlement of Yi minority people in China, is the area affected most severely by HIV in China [2]. By the end of 2018, there have been 38,545 PLWH reported in Liangshan, and prevalence rates of HIV in five counties were the highest in China [3, 4]. Effective HIV interventions should be formatted to reduce HIV transmission in this area.
Antiretroviral therapy (ART) is highly effective in suppressing HIV, stopping the progression of HIV disease and reducing the risk of HIV transmissions [5, 6]. The rapid scale-up of ART could lead to a significant decline in morbidity and mortality among PLWH, which has been confirmed by many studies [5, 7, 8]. ART is a long-term treatment with the potential for drug toxicity and the emergence of HIV resistance, setting the stage for a suboptimal response or lack of sustained response to therapy that is defined as virological failure. Unfortunately, virological failure not only compromises therapeutic effects for individuals but also endangers the population as a whole [9]. In Liangshan, the virological failure rate is reported to be about 36–45% [10, 11], which is more serious than average in China [12], mainly due to the poor adherence to ART and inadequate drug levels. The high prevalence of virological failure may lead to a large extent of genotypic HIV-1 drug resistance. When an individual is infected with drug resistance mutations, the resistant strain may become the dominant strain for further transmission of HIV-1 drug resistance [13], and consequently increasing the number of antiretroviral-naive patients and reducing their therapeutic effectiveness [14]. Understanding the risk factors of virological failure could help to target HIV prevention and intervention strategies [15].
HIV is characterized by its great genetic variability and responsibility for developing drug-resistant mutations with high viral replication rates. This not only increases the risk of virological failure on antiretroviral treatment, but also results in the spread of drug-resistant strains, which brings a huge challenge to controlling the HIV epidemic and preventing the HIV spread. The genotype of HIV-1 is related to the route of transmission, and there are differences in epidemic scale and distribution characteristics [16, 17]. The HIV-1 genotype distribution had been described in parts of China [18, 19]. However, little data is known about that in the highest HIV epidemic area of China. Therefore, we aimed to analyze prevalence and determinants of ART failure, and understand the genetic diversity and drug resistance among PLWH, which could help us better understand HIV epidemiology and allow a timely modification of ART guidelines in this area.

Methods

Study participants

Participants were recruited through a multi-stage cluster sampling strategy. The county with the most severe HIV epidemic was selected from all 17 counties in Liangshan Prefecture. According to the basic information system for Acquired Immune Deficiency Syndrome (AIDS) prevention and treatment, all PLWH in this county were included in our study. We have tried to identify as many PLWH as possible through all three possible channels: (1) Provider-Initiated HIV Testing & Counseling (PITC) service for HIV, (2) Voluntary Counseling and Testing (VCT) service through fixed VCT sites and non-government organizations (NGOs), (3) HIV sentinel surveillance (HSS) for unmarried youths, pregnant women, community population, and drug users. The inclusion criteria for PLWH were: (1) receiving confirmatory HIV diagnosis, (2) being permanent residents or had stayed in Liangshan area for more than 5 years, (3) receiving ART in the local township health center for more than 6 months. The exclusion criteria for participants were having have major psychiatric illness (e.g., schizophrenia and bipolar disorder.
According to the inclusion criteria and exclusion criteria, medical staff phoned candidate participants about the study and confirmed their eligibility to join the study. All participants signed informed consent forms before enrollment. Finally, a total of 5157 PLWH were included into the study.

Data collection

Questionnaire was used to ask all participants in private rooms to collected the socio-demographic information, possible route of HIV transmission, HIV-related behaviors and disease-related characteristics. The socio-demographic information including gender, age, occupation, current marital status, ethnicity, education level. The route of HIV transmission included drug injection, heterosexual behaviors and drug injection, casual sexual behavior and risk behaviors related to mother-to-child transmission treatment time. The HIV-related behaviors included information about needle sharing, number of casual sexual partners and history of sexually transmitted disease except for HIV. The disease related characteristics were extracted from their medical record, including viral load, stage of the disease, the initial regimen and time of ART and change of ART regimen. The above information was collected from National AIDS reporting system. When a newly diagnosed with HIV-1 infection was found or received ART, the detailed information (the initial regimen and time of ART) would be collected and inputted into system.

Laboratory tests

Each participant was asked to provide 5 mL of venous blood for detecting the viral load of HIV-1. The plasma samples were isolated from each participant, and preserved in a − 80 °C freezer until analysis. HIV viral load was measured in the Sichuan Center for Disease Control and Prevention. Virological failure in ART was defined as HIV RNA level ≥ 1000 copies/ml [20, 21] after receiving ART for more than 6 months.

Nucleic acid extraction, amplification, sequencing and drug-resistance analyses

Total viral nucleic acid was extracted from 200-μl plasma using an automatic extraction machine (MagNA Pure LC 2.0 system, Roche, Branchburg, NJ, USA). The full-length protease gene in Pol region and the first 300 codons of the reverse transcriptase gene was amplified by using reverse transcription polymerase chain reaction (RT-PCR). The amplified products were purified in and sequenced at Beijing Genomics Research Center Ltd., in China.
The HIV-1 pol sequences obtained in the study, together with reference sequences of different subtypes and CRFs, were edited and aligned using ChromasProl.33, and the sequence alignments were manually performed by BIOEDIT Sequence Alignment Editor software (Ibis Biosciences, Carlsbad, CA, USA). The detailed amplification, sequencing and drug resistance analyses were detailed described previously [22, 23].

Statistical analysis

Data were analyzed using SPSS version 21.0 for Windows (SPSS, Inc., Chicago, IL, USA). Categorical variables were expressed as frequencies and percentages and compared using the chi-squared (χ2) test. Using the presence of virological failure in ART as the dependent variable, univariate odds ratios (ORu) and 95% confidence interval (CI) for socio-demographic information, possible route of HIV transmission, HIV-related behaviors and disease-related characteristics were estimated. A summary model was obtained by fitting a multiple regression model that considered all variables that were significant in the respective univariate analysis as candidates. Multivariate odds ratios (ORm) and respective 95%CI were obtained. Was used for data analysis, with p < 0.05 taken as statistically significant.

Results

Prevalence and determinants of virological failure on ART among PLWH

A total of 2156 (41.81%) PLWH showed virological failure on ART from 2016 to 2017. Among PLWH with virological failure, majority of them were male, peasant, married, illiteracy, Yi minority, having HIV transmission route of drug injection, the first CD4+ counts of 200 ~ 500 counts/ul, having never used illicit drugs and shared the needle, having no casual sexual partners and history of sexually transmitted diseases except for HIV (Table 1).
Table 1
Prevalence and determinants of virological failure on ART among PLWH
Variables
VL ≥ 1000 copies/ml
Total N
ORu
ORm
Virologic failure
n = 2156 (rate, n/N%)
Socio-demographics
Gender
  Female
710 (36.90)
1925
1.0(ref)
1.0(ref)
  Male
1446 (44.70)
3232
1.39 (1.23–1.56)***
1.25 (1.03–1.50)***
Age
  ≤ 15
172 (48.86)
352
1.0 (Ref.)
 
  15 ~ 40
1423 (41.45)
3433
0.74 (0.59–0.92) ***
 
  >40
533 (40.94)
1302
0.72 (0.57–0.92) ***
  Unknown
28 (40.00)
70
 
Occupation
  Employed
37 (34.91)
106
1.0 (Ref.)
 
  Peasant
1736 (41.85)
4148
1.34 (0.90–2.01)
 
  Students and children
136 (46.74)
291
1.64 (1.03–2.60)**
  Unknown
247 (40.36)
612
 
Current marital status
  Married
1406 (41.80)
3366
1.0 (Ref.)
 
  Single
428 (45.77)
934
1.18 (1.02–1.36) **
 
  Widowed or Divorced
99 (35.87)
276
0.78 (0.60–1.01)*
  Unknown
223 (38.38)
581
 
Ethnicity
(0.00)
   
  Yi
2137 (41.70)
5125
1.0 (Ref.)
 
  Han and others
19 (59.38)
32
2.04 (1.01–4.15)**
Education level
  Illiteracy
1339 (42.58)
3145
1.0 (Ref.)
1.0 (Ref.)
  Primary school
581 (40.77)
1425
0.93 (0.82–1.05)*
0.77 (0.66–0.89)**
  Secondary or above
70 (38.67)
181
0.85 (0.63–1.16)
0.69 (0.46–1.04)
  Unknown
166 (40.89)
406
 
HIV transmission route
  Heterosexual behaviors
715 (37.10)
1927
1.0 (Ref.)
1.0 (Ref.)
  Drug injection
747 (43.08)
1734
1.28 (1.12–1.47)***
1.12 (0.93–1.35)
  Heterosexual behaviors and drug injection
325 (49.02)
663
1.63 (1.36–1.95) ***
1.44 (1.15–1.82)**
  Mother to child
163 (48.95)
333
1.63 (1.29–2.05) ***
1.58 (1.21–2.08)**
  Others and unknown
206 (41.20)
500
The first CD4+counts, counts/ul
  ≤ 200
346 (46.82)
739
1.0 (Ref.)
 
  200 ~ 500
986 (41.29)
2388
0.80 (0.68–0.94)**
 
  >500
646 (40.68)
1588
0.78 (0.65–0.93)**
  Unknown
178 (40.27)
442
 
Stage of disease
  HIV
784 (37.44)
2094
1.0 (Ref.)
1.0 (Ref.)
  AIDS
985 (44.49)
2214
1.34 (1.19–1.51) ***
1.35 (1.17–1.55)***
  Unknown
387 (45.58)
849
 
HIV-related behaviors
Needle sharing
  Had never used illicit drugs and shared the needle
1001 (39.03)
2565
1.0 (Ref.)
1.0 (Ref.)
  Had shared needle for 1 ~ 4 times
519 (43.43)
1195
1.20 (1.04–1.38)**
1.34 (1.09–1.65)**
  Had shared needle ≥5 times
421 (48.00)
877
1.44 (1.24–1.68) ***
1.52 (1.21–1.91)***
  Unknown
215 (41.35)
520
 
Number of casual sexual partners
  0
1089 (42.51)
2562
1.0 (Ref.)
 
  1 ~ 4
508 (38.99)
1303
0.86 (0.75–0.99)**
 
  ≥ 5
344 (44.56)
772
1.09 (0.92–1.28)
  Unknown
215 (41.35)
520
 
History of sexually transmitted diseases except for HIV
  Never
1494 (42.53)
3513
1.0 (Ref.)
 
  Ever
100 (38.46)
260
0.85 (0.65–1.09)
ART related information
Time of ART
  < 12
304 (43.55)
698
1.0 (Ref.)
1.0 (Ref.)
  12 ~ 36
682 (40.38)
1689
0.88 (0.73–1.05)*
0.72 (0.60–0.92)**
  > 36
728 (40.00)
1820
0.86 (0.72–1.03)*
0.66 (0.53–0.83)***
  Unknown
442 (46.53)
950
 
Initial regimen of ART
  TDF + 3TC + EFV/NVP
1202 (39.97)
3007
1.0 (Ref.)
 
  AZT + 3TC + EFV/NVP
444 (44.36)
1001
1.20 (1.04–1.38)**
 
  LPV/r + 3TC + AZT/TDF
48 (33.33)
144
0.75 (0.53–1.07)*
 
  Unknown
462 (45.97)
1005
=
Replacement of ART regimen
  Never
1535 (40.16)
3822
1.0 (Ref.)
1.0 (Ref.)
  Ever
181 (46.65)
388
1.30 (1.06–1.61)**
1.48 (1.12–1.96)**
ORu univariate odds ratios, ORm multivariate odds ratios, CI confidence interval, TDF tenofovir, 3TC lamivudine, NVP nevirapine, EFV efavirenz, AZT Zidovudine, LPV/r fosamprenavir/ritonavir
Variables with p < 0.2 in the univariate analysis as candidates were selected by a summary multiple logistic regression model
*P value< 0.2; **P value< 0.05; ***P value< 0.001
In univariate analysis, gender, age, occupation, current marital status, ethnicity, HIV transmission route, CD4+ level, stage of disease, needle sharing and the number of casual sexual partners, the initial regimen of ART and change of ART regimen were significantly associated with risk of virological failure on ART (p < 0.05). In multivariate logistic regression model, we found that males, heterosexual behaviors and drug injection and mother to child transmission routes, stage of AIDS, having used illicit drugs and shared the needles, having ever replaced ART regimen significantly increased the risk of virological failure among PLWH (p < 0.05), while higher education level and time on ART ≥12 months were associated with lower likelihood of virological failure (p < 0.05) (Table 1).

Prevalence of drug resistance among PLWH with virological failure on ART

Drug-resistant mutation in 1576 (73.10%, 1576/2156) samples were successfully detected. The phylogenetic analyses based on the pol regions showed that CRF07_BC (1508, 95.62%) were the most common strains in this area, and followed by CRF08_BC (42, 2.66%) and C (26, 1.72%) subtypes were the most common strains in Sichuan province (Fig. 1).
Among PLWH with virological failure, the drug-resistant rate was as high as 32.10% (507/1576). The prevalence of drug resistance was high in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in all treatment regimens, then followed by nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) (Table 2). The high frequencies of drug resistance were found in Efavirenz (EFV) and Nevirapine (NVP) of NNRTIs, Abacavir (ABC), Emtricitabine (FTC) and Lamivudine (3TC) of NRTIs, and tipranavir / ritonavir (TPV/r) in PIs. The LPV/r + 3TC + AZT/TDF regimen showed the lowest drug resistance to PIs, NRTIs, and NNRTIs compared to the other two regimens.
Table 2
Prevalence of drug resistance among PLWH with virological failure on ART
 
TDF + 3TC + NVP/EFV
AZT + 3TC + NVP/EFV
LPV/r + 3TC + AZT/TDF
Others
Total
n = 928 (%)
n = 318 (%)
n = 47 (%)
N = 283 (%)
N = 1576 (%)
PIs
13 (1.40)
9 (2.83)
1 (2.13)
6 (2.12)
35 (2.22)
 ATV/r
1 (0.35)
2 (0.13)
 DRV/r
 FPV/r
1 (0.31)
1 (0.35)
3 (0.19)
 IDV/r
1 (0.35)
2 (0.13)
 LPV/r
1 (0.35)
2 (0.13)
 NFV
1 (0.11)
1 (0.31)
2 (0.71)
6 (0.38)
 SQV/r
1 (0.35)
2 (0.13)
 TPV/r
12 (1.29)
8 (2.52)
1 (2.13)
5 (1.77)
31 (1.97)
NRTIs
97 (10.45)
55 (17.30)
2 (4.26)
39 (13.78)
232 (14.72)
 ABC
92 (9.91)
55 (17.30)
2 (4.26)
39 (13.78)
227 (14.40)
 AZT
26 (2.80)
22 (6.92)
2 (4.26)
8 (2.83)
66 (4.19)
 D4T
44 (4.74)
26 (8.18)
2 (4.26)
19 (6.71)
110 (6.98)
 DDI
45 (4.85)
25 (7.86)
2 (4.26)
19 (6.71)
110 (6.98)
 FTC
91 (9.81)
55 (17.30)
2 (4.26)
39 (13.78)
226 (14.34)
 3TC
91 (9.81)
55 (17.30)
2 (4.26)
39 (13.78)
226 (14.34)
 TDF
30 (3.23)
18 (5.66)
1 (2.13)
16 (5.65)
81 (5.14)
NNRTIs
269 (28.99)
108 (33.96)
10 (21.28)
90 (31.80)
567 (35.98)
 EFV
261 (28.13)
103 (32.39)
10 (21.28)
88 (31.10)
550 (34.90)
 ETR
63 (6.79)
42 (13.21)
1 (2.13)
24 (8.48)
154 (9.77)
 NVP
261 (28.13)
105 (33.02)
10 (21.28)
88 (31.10)
552 (35.03)
 RPV
96 (10.34)
58 (18.24)
1 (2.13)
35 (12.37)
225 (14.28)
TDF Tenofovir, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, AZT Zidovudine, LPV/r Fosamprenavir/ritonavir, ATV/r Atazanavir/ritonavir, DRv/r Darunavir/ritonavir, FPV/r Fosamprenavir/ritonavir, IDV/r Indinavir/Ritonavir, NFV Nelfinavir, SQV/r Ritonavir-boosted saquinavir, TPV/r Tipranavir/ritonavir, ABC Abacavir, D4T Stavudine, DDI Didanosine, FTC Emtricitabine, ETR Etravirine, RPV Rilpivirine

Antiretrovairal resistance mutations

The drug-resistant mutation frequency to NNRTIs (35.98%,567/1576) was much higher than that to NRTIs (14.72%,232/1576) and PIs (2.22%,35/1576) among PLWH with virological failure. The most common mutations in NNRTIs were K103N/KN (64.69%), V179D/E (23.47%) and Y181C/YC/I (14.00%), they were M184V/MV/I (36.29%), T215F/FS/TNSY (7.50%) and K219Q (5.92%) in NRTIs, and they were Q58E/QE (4.93%), L10F/LFI (0.39%) and M46L (0.39%) in PIs (Fig. 2).

Discussion

The findings confirmed that the prevalence of virological failure on ART (41.81%) among PLWH was high in this area. A high prevalence of subtype CRF07_BC (95.62%) was observed among PLWH with virological failure on ART, which was different from other areas of China [24, 25]. Thus, it is a great challenge to successfully suppress HIV and decrease drug resistance in PLWH in this area.
Our study found that male PLWH and illiteracy were associated with a higher likelihood of incomplete viral suppression of virological failure on ART. Compared to females, males are more likely to discontinue from ART, which results in virological failure [26, 27]. Part of the reasons for this may be explained by (1) Compared to women, men generally have poorer healthcare-seeking behaviors, poorer ART uptake and a higher risk of immunotherapy failure observed in this study [28] (2) Women have a lower body mass index and are more likely to maintain a higher concentration of drugs in their bodies than men, so they are more likely to achieve viral suppression [29], (3) Men have more unhealthy behaviors such as smoking and drinking than women, which can lead to poorer adherence to medication and lower overall treatment success [30]. Illiteracy patients often lack sufficient understanding of the importance of ART and regular medication, as well as lack of communication skills with physicians [31, 32], which may increase the risk of virological failure. Therefore, it is necessary to develop effective measures to promote drug compliance of ART targeting males PLWH and illiteracy in Liangshan.
We also found that patients who had been on ART ≤12 months, and had changed ART regimens were more likely to experience virologic failure. Time on ART ≤12 months was associated with a high risk of virological failure than time on ART ≥12 months. This result was similar to a finding from a study in Zimbabwe, which showed that compare to time on ART ≥4 years, patients whose time on ART ≤4 years had more risk of treatment failure. Because the latter may have taken the wrong medicine or forgotten it due to lack of experience [30, 31]. Therefore, the current results all suggest the necessity of increasing the medication guidance, strengthening the management of treatment follow-up, and urging the patients to take medicine on time and following the prescribed amount [32]. Finally, the replacement of the ART regimen was also associated with virological failure. Patients who had replaced the ART regimen were more likely to experience treatment failure, possibly because they were not systematically tested for viral load and drug resistance before replacement [33]. However, our study didn’t obtain the information on the reasons for the replacement of the ART regimen. Therefore, the capacity of doctors should be improved, and the process of changing the ART regimen should be standardized. Viral load and drug resistance detection should be required before the replacement of the ART regimen.
Our studies found that the subtype CRF07_BC (95.62%) was most prevalent and was the predominant subtype, followed by CRF08_BC. CRF07_BC, which was one of the most prevalent CRFs in China [3439] and was first identified in the intravenous drug use (IDU) population in Xinjiang in 1997 [38, 39]. CRF07_BC was first introduced into Yunnan and then spread into Sichuan and Gansu, and finally to Xinjiang along drug transporting routes [40, 41]. Liangshan is located along the drug trafficking routes from the “Golden Triangle” to the northwest and central China, and injection drug use was the main infection risk factors of HIV infection and about 33.2–56.9% of the new HIV-1 patients were drug users [42], and it can be assumed that CFR07_BC strain is prevalent in this area. Given the changing profile of the HIV epidemic with the shift of high-risk behaviors from IDU to sexual contact, the heterosexual transmission has surpassed injective drug use and became the predominant route of HIV transmission in this area [2, 3]. The dominant prevalent of CRF07_BC illustrated that infected IDUs are the main source of transmission to other populations.
According to our findings, drug-resistant frequency to NNRTIs was much higher than that to NRTIs and PIs in this area among PLWH with virologic failure in ART. A similar pattern was also found in other places in China and low- and middle-income countries [4346], but the prevalence of NNRTI resistance in this area is lower than in other places (50–90%) [47]. Thus, the high prevalence of virologic failure in ART and related low prevalence of drug resistance may be mainly attributed to poor treatment adherence, and strategies are needed to improve treatment adherence and reduce the treatment failure in ART.
There were several limitations in this study. First, this study was a cross-sectional survey, time-based sequence and cause-effect relationships among these variables cannot be established. Second, some HIV related behaviors were self-reporting, which may lead to recall bias. Third, some important factors of treatment failure in ART, such as ART adherence, should be considered as potential factors in our study, but such information did not collect during the follow-up. Fourth, the participants enrolled in the study were not newly diagnosed with HIV-1 infection, and some patients may have pretreatment drug resistance. Therefore, we could not identify the time of virologic failure and the resistance to ART before and after genotyping in the first virologic failure.

Conclusions

The findings confirmed that the prevalence of incomplete viral suppression of ART virologic failure in ART among PLWH was high in this area. On the one hand, we should develop more suitable health education measures for medication compliance for this kind of population; on the other, the early identification of the drug resistance of PLWH with ART virologic failure are of great significance. Timely replacement of new regimens for PLWH with drug resistance could prevent additional drug resistance mutation or multiple drug resistance. Last but not the least, continuum in care and retention in care are important factors in preventing virological failure [48], and enhanced understandings of adherence and adherence interventions for less healthy individuals are required to reduce the virological failure. Also, understanding the genotype distribution and drug resistance may contribute to designing target preventive interventions for improving treatment efficiency, aiming for the selection of more effective therapeutic regimens to promote viral suppression and prevent HIV-1 transmission.

Acknowledgments

The authors would like to thank the Center for AIDS/STD Control and Prevention, Sichuan Center for Disease Control and Prevention, Liangshan Center for Disease Control and Prevention and Butuo Center for Disease Control and Prevention to support data.
All subjects voluntarily participated in our study and signed informed consent forms before enrollment. For participants under 16 years old, written informed consent was obtained from their parents or guardians. The study protocol was approved by the Ethics Committee of the Sichuan Center for Disease Control and Prevention (201303), and the study was carried out following the Helsinki Declaration of 1964.
Not application.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Yang S, Luo M, Zhang S, Yao Y, Wang Q, Liao Q. Overview on culture and customs related to AIDS epidemic and prevention among Yi people in Liangshan. Chin J AIDS STD. 2017;23(3):101–5. Yang S, Luo M, Zhang S, Yao Y, Wang Q, Liao Q. Overview on culture and customs related to AIDS epidemic and prevention among Yi people in Liangshan. Chin J AIDS STD. 2017;23(3):101–5.
3.
Zurück zum Zitat Zhao QG, Gong YH, Liao Q, Yu G, Wang K, Wang J, et al. Estimation on the HIV-1 incidence in Liangshan Yi autonomous prefecture, under BED-capture enzyme immunoassay, from 2011 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(8):1105–7.PubMed Zhao QG, Gong YH, Liao Q, Yu G, Wang K, Wang J, et al. Estimation on the HIV-1 incidence in Liangshan Yi autonomous prefecture, under BED-capture enzyme immunoassay, from 2011 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(8):1105–7.PubMed
4.
Zurück zum Zitat Sun X, Lu F, Wu Z, Poundstone K, Zeng G, Xu P, et al. Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol. 2010;1(Suppl 2):ii4–13. Sun X, Lu F, Wu Z, Poundstone K, Zeng G, Xu P, et al. Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol. 2010;1(Suppl 2):ii4–13.
5.
Zurück zum Zitat Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA. 2014;312(4):410–25.PubMed Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA. 2014;312(4):410–25.PubMed
6.
Zurück zum Zitat Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentral
7.
Zurück zum Zitat Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–7.PubMed Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–7.PubMed
8.
Zurück zum Zitat Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–7.PubMedPubMedCentral Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–7.PubMedPubMedCentral
9.
Zurück zum Zitat Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal. 2013;27(5):346–53.PubMedPubMedCentral Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal. 2013;27(5):346–53.PubMedPubMedCentral
10.
Zurück zum Zitat Yang CB, Yang W, Zeng YL, Gu XD, Bian SC, Wu M, et al. Effect of early antiretroviral therapy on acquired immune deficiency syndrome in Butuo County, Liangshan autonomous prefecture. West China Med J. 2017;32(6):867–70. Yang CB, Yang W, Zeng YL, Gu XD, Bian SC, Wu M, et al. Effect of early antiretroviral therapy on acquired immune deficiency syndrome in Butuo County, Liangshan autonomous prefecture. West China Med J. 2017;32(6):867–70.
11.
Zurück zum Zitat Xu JL, Jike KCN, Ma Y, Yu G, Wang J, Wang K, et al. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi autonomous refecture, Sichuan Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(6):668–72.PubMed Xu JL, Jike KCN, Ma Y, Yu G, Wang J, Wang K, et al. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi autonomous refecture, Sichuan Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(6):668–72.PubMed
12.
Zurück zum Zitat Dou Z, Zhang F, Zhao Y, Jin C, Zhao D, Gan X, et al. Progress on China s national free antiretroviral therapy strategy in 2002-2014. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36(12):1345–50.PubMed Dou Z, Zhang F, Zhao Y, Jin C, Zhao D, Gan X, et al. Progress on China s national free antiretroviral therapy strategy in 2002-2014. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36(12):1345–50.PubMed
13.
Zurück zum Zitat Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.PubMedPubMedCentral Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.PubMedPubMedCentral
14.
Zurück zum Zitat Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Resistance. UCGoHD: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208(9):1459–63.PubMedPubMedCentral Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Resistance. UCGoHD: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208(9):1459–63.PubMedPubMedCentral
15.
Zurück zum Zitat Leigh Brown AJ, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn DT. Collaboration. UHDR: transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 2011;204(9):1463–9.PubMedPubMedCentral Leigh Brown AJ, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn DT. Collaboration. UHDR: transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 2011;204(9):1463–9.PubMedPubMedCentral
16.
Zurück zum Zitat Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66(5):391–400. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66(5):391–400.
17.
Zurück zum Zitat Song YX, Xin RL, Li ZC, Yu HW, Lun WH, Ye J, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–44.PubMed Song YX, Xin RL, Li ZC, Yu HW, Lun WH, Ye J, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–44.PubMed
18.
Zurück zum Zitat Xiao P, Zhou Y, Lu J, Yan L, Xu X, Hu H, et al. HIV-1 genotype diversity and distribution characteristics among heterosexually transmitted population in Jiangsu province, China. Virol J. 2019;16(1):51.PubMedPubMedCentral Xiao P, Zhou Y, Lu J, Yan L, Xu X, Hu H, et al. HIV-1 genotype diversity and distribution characteristics among heterosexually transmitted population in Jiangsu province, China. Virol J. 2019;16(1):51.PubMedPubMedCentral
19.
Zurück zum Zitat Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, et al. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir. 2016;32(9):851–9.PubMed Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, et al. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir. 2016;32(9):851–9.PubMed
20.
Zurück zum Zitat Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. HIV Med. 2019;20(9):624–7.PubMed Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. HIV Med. 2019;20(9):624–7.PubMed
21.
Zurück zum Zitat Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Achieng B, et al. SESOTHO trial (“switch either near suppression or THOusand”) - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, southern Africa. BMC Infect Dis. 2018;18(1):76.PubMedPubMedCentral Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Achieng B, et al. SESOTHO trial (“switch either near suppression or THOusand”) - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, southern Africa. BMC Infect Dis. 2018;18(1):76.PubMedPubMedCentral
22.
Zurück zum Zitat Yuan D, Su L, Liu H, Yu H, Yang H, Ye L, et al. Drug-resistance characteristics of CRF01_AE and CRF07_BC subtypes of HIV-1 strains in Sichuan province. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(10):901–6.PubMed Yuan D, Su L, Liu H, Yu H, Yang H, Ye L, et al. Drug-resistance characteristics of CRF01_AE and CRF07_BC subtypes of HIV-1 strains in Sichuan province. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(10):901–6.PubMed
23.
Zurück zum Zitat Yuan D, Du Z, Zhou J, Ye L, Su L, Yang H, et al. HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017. Medicine (Baltimore). 2019;98(43):e17585. Yuan D, Du Z, Zhou J, Ye L, Su L, Yang H, et al. HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017. Medicine (Baltimore). 2019;98(43):e17585.
24.
Zurück zum Zitat Xiaoli C, Yun L, Junbin L, Fengyu H, Weiping C. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS STD. 2015;21(5):369–72. Xiaoli C, Yun L, Junbin L, Fengyu H, Weiping C. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS STD. 2015;21(5):369–72.
25.
Zurück zum Zitat Maojiao L. Analysis of genotype resistance variation and subtypes of HIV-1 in Honghe prefecture, Yunnan. Dali: Dali University; 2018. Maojiao L. Analysis of genotype resistance variation and subtypes of HIV-1 in Honghe prefecture, Yunnan. Dali: Dali University; 2018.
26.
Zurück zum Zitat Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with Virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014-July 2015. BMC Infect Dis. 2017;17(1):326.PubMedPubMedCentral Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with Virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014-July 2015. BMC Infect Dis. 2017;17(1):326.PubMedPubMedCentral
27.
Zurück zum Zitat Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824.PubMedPubMedCentral Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824.PubMedPubMedCentral
28.
Zurück zum Zitat Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Doran C, Zhang L. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538–44.PubMed Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Doran C, Zhang L. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538–44.PubMed
29.
Zurück zum Zitat Jordan MR, Obeng-Aduasare Y, Sheehan H, Hong SY, Terrin N, Duong DV, et al. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2014;25(9):662–8.PubMed Jordan MR, Obeng-Aduasare Y, Sheehan H, Hong SY, Terrin N, Duong DV, et al. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2014;25(9):662–8.PubMed
30.
Zurück zum Zitat Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther. 2009;6:7.PubMedPubMedCentral Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther. 2009;6:7.PubMedPubMedCentral
31.
Zurück zum Zitat Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5–8):29–36.PubMed Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5–8):29–36.PubMed
32.
Zurück zum Zitat Jean Louis F, Buteau J, Francois K, Hulland E, Domercant JW, Yang C, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.PubMedPubMedCentral Jean Louis F, Buteau J, Francois K, Hulland E, Domercant JW, Yang C, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.PubMedPubMedCentral
33.
Zurück zum Zitat Kyaw NT, Harries AD, Kumar AM, Oo MM, Kyaw KW, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One. 2017;12(2):e0171780.PubMedPubMedCentral Kyaw NT, Harries AD, Kumar AM, Oo MM, Kyaw KW, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One. 2017;12(2):e0171780.PubMedPubMedCentral
34.
Zurück zum Zitat Yu X-F, Chen J, Shao Y, Beyrer C, Lai S. Two subtypes of HIV-1 among injection-drug users in southern China. Lancet. 1998;351:9111. Yu X-F, Chen J, Shao Y, Beyrer C, Lai S. Two subtypes of HIV-1 among injection-drug users in southern China. Lancet. 1998;351:9111.
35.
Zurück zum Zitat Yu ES, Xie Q, Zhang K, Lu P, Chan LL. HIV infection and AIDS in China, 1985 through 1994. Am J Public Health. 1996;86(8):1116–22.PubMedPubMedCentral Yu ES, Xie Q, Zhang K, Lu P, Chan LL. HIV infection and AIDS in China, 1985 through 1994. Am J Public Health. 1996;86(8):1116–22.PubMedPubMedCentral
36.
Zurück zum Zitat Lin YT, Lan YC, Chen YJ, Huang YH, Lee CM, Liu TT, et al. Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan. J Infect Dis. 2007;195(9):1283–93.PubMed Lin YT, Lan YC, Chen YJ, Huang YH, Lee CM, Liu TT, et al. Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan. J Infect Dis. 2007;195(9):1283–93.PubMed
37.
Zurück zum Zitat He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012;7(10):e47289.PubMedPubMedCentral He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012;7(10):e47289.PubMedPubMedCentral
38.
Zurück zum Zitat Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol. 2000;74(23):11367–76.PubMedPubMedCentral Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol. 2000;74(23):11367–76.PubMedPubMedCentral
39.
Zurück zum Zitat Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000;74(23):11286–95.PubMedPubMedCentral Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000;74(23):11286–95.PubMedPubMedCentral
40.
Zurück zum Zitat Tee KK, Pybus OG, Li XJ, Han X, Shang H, Kamarulzaman A, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol. 2008;82(18):9206–15.PubMedPubMedCentral Tee KK, Pybus OG, Li XJ, Han X, Shang H, Kamarulzaman A, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol. 2008;82(18):9206–15.PubMedPubMedCentral
41.
Zurück zum Zitat Zhefeng M, Jingyun L, Ping Z, Jianqing X, Xiaoyan Z. A new transmission map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. Retrovirology. 2012;9(S2):P139.PubMedCentral Zhefeng M, Jingyun L, Ping Z, Jianqing X, Xiaoyan Z. A new transmission map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. Retrovirology. 2012;9(S2):P139.PubMedCentral
42.
Zurück zum Zitat Qixing W, Suhua Z, Shujuan Y, Qiang L, Gang Y, Yongnan Y, et al. Characteristics of transmission route among the reported HIV infections during 2011-2014 in Liangshan prefecture. Chin J AIDS STD. 2017;23(8):719–22. Qixing W, Suhua Z, Shujuan Y, Qiang L, Gang Y, Yongnan Y, et al. Characteristics of transmission route among the reported HIV infections during 2011-2014 in Liangshan prefecture. Chin J AIDS STD. 2017;23(8):719–22.
43.
Zurück zum Zitat Hou LJ, Wang HW, Duan SP, Zhuo Y, Zhou YC, Wu HJ, et al. The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. Arch Virol. 2015;160(8):2051–61.PubMed Hou LJ, Wang HW, Duan SP, Zhuo Y, Zhou YC, Wu HJ, et al. The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. Arch Virol. 2015;160(8):2051–61.PubMed
44.
Zurück zum Zitat Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014;6(10):4095–139.PubMedPubMedCentral Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014;6(10):4095–139.PubMedPubMedCentral
45.
Zurück zum Zitat Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci. 2002;23(8):381–8.PubMed Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci. 2002;23(8):381–8.PubMed
46.
Zurück zum Zitat Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob Chemother. 2017;72(1):227–34.PubMed Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob Chemother. 2017;72(1):227–34.PubMed
47.
Zurück zum Zitat WHO. HIV drug resistance report 2017. Geneva: World Health Organization; 2017. WHO. HIV drug resistance report 2017. Geneva: World Health Organization; 2017.
48.
Zurück zum Zitat Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019;19(1):312.PubMedPubMedCentral Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019;19(1):312.PubMedPubMedCentral
Metadaten
Titel
Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study
verfasst von
Dan Yuan
Meijing Liu
Peng Jia
Yiping Li
Yuling Huang
Li Ye
Laze Api
Maogang Chen
Liang Yao
Zixin Wang
Honglu Liu
Shu Liang
Shujuan Yang
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2020
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05124-1

Weitere Artikel der Ausgabe 1/2020

BMC Infectious Diseases 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.